SAINT LAURENT, Quebec, May 14, 2021 (GLOBE NEWSWIRE) IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films,…
Atai Life Sciences Psychedelics IPO Key Takeaway From S-1 Filing businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.
The filing shows that ATAI has raised an aggregate of $362.3 million from private investors so far.
It is planning to sell its shares on New York s tech-focused Nasdaq market under the symbol ATAI. A date for the IPO has not been set.
Underwriters for the IPO include Credit Suisse, Citigroup, Cowen, and Berenberg.
ATAI, which describes itself as a drug development platform, was set up to acquire, incubate and develop psychedelics and other drugs that can be used to treat depression, anxiety, addiction and other mental health conditions.
The company, which has roughly 50 staff in offices across Berlin, New York and San Diego, is currently partnered with 14 companies focusing on drug development and other technologies. In exchange for a majority stake in the drugs and technologies they re developing, ATAI helps the scientists to raise money, work with the regulators, and conduct clinical trials. None of ATAI s drugs have been formally approved by regulators to date.
ATAI, which describes itself as a drug development platform, was set up to acquire, incubate and develop psychedelics and other drugs that can be used to treat depression, anxiety, addiction and other mental health conditions.
The Berlin-headquartered company founded in 2018 by entrepreneurs Christian Angermayer, Florian Brand, Lars Wilde and Srinivas Rao announced its majority stake in Psyber on Wednesday. It declined to specify what it offered Psyber in exchange for the majority stake.
In theory, a brain computer interface allows direct communication between a human brain and an external device.
ATAI said that Psyber s brain computer interface technology, which is in the early stages of development, could one day help patients understand how drugs impact activity in their brain, while also improving the efficacy and safety of its drugs.
Peter Thiel-Backed Firm Takes Majority Stake in a Brain Computer Interface Start-Up nbcconnecticut.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nbcconnecticut.com Daily Mail and Mail on Sunday newspapers.